About Cempra
Cempra is a company based in Chapel Hill (United States) founded in 2006. Cempra has raised $149.5 million across 8 funding rounds from investors including Fujifilm, Cubist Pharmaceuticals and Ontario Teachers' Pension Plan. The company has 78 employees. Cempra operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Chapel Hill, United States
- Employees 78
- SectorsHealthcare
- Website cempra.com
- Social LinkedIn X
- Legal Name Cempra Pharmaceuticals, Inc.
- Total Equity Funding$149.5M (USD)
in 8 rounds
- Latest Funding Round$10M (USD), Post-IPO
Sep 2014
- InvestorsFujifilm
& 6 more
- Employee Count78
Funding Insights of Cempra
Cempra has successfully raised a total of $149.5M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $149.5M
- Total Rounds 8
- Last Round Post-IPO — $10M
- First Round $22M
(Oct 2006)
- Investors Count 7
All 8 funding rounds of Cempra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2014 | $10M | Post-IPO | – | – | |
| Oct 2012 | $25.12M | Post-IPO | – | – | – |
| Aug 2011 | $5M | Debt – Convertible | – | – | – |
| May 2010 | $46M | Series C | – | – | – |
| May 2009 | $25.5M | Series C | – | – | – |
| May 2009 | $46M | Series C | – | Quaker Partners, Devon Park BioVentures | |
| Dec 2007 | $10M | Series B | – | – | |
| Oct 2006 | $22M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Cempra
Cempra has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Fujifilm, Cubist Pharmaceuticals and Ontario Teachers' Pension Plan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | dpbioventures.com | - | |
PE firm investing in the US | – | aislingcapital.com | New York, United States | |
Early-stage life sciences and tech focused VC firm funding companies in the US | – | intersouth.com | Durham, United States | |
Multiple sectors are invested in by the venture capital firm. | 1934 | fujifilm.com | Minato, Japan | |
- | – | quakerbio.com | - | |
Pension funds focused on multiple sectors | 1990 | otpp.com | Toronto, Canada | |
Pharmaceuticals for acute care bacterial infections are developed and commercialized. | 1993 | cubist.com | Lexington, United States |
Investor details for Cempra
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cempra
15 people are tracked at Cempra (10 in leadership, 3 in board & advisors, 2 in team); the tracked headcount is 78.
| Name | Role | Group |
|---|---|---|
John Harlow | Chief Commercial Officer | Leadership |
Christine Ann Miller | President & CEO | Leadership |
Kristen Allgor | Chief Human Resources Officer | Leadership |
Kelley Ford | VP, Manufacturing & Supply | Leadership |
Susan Blum | Chief Financial Officer | Leadership |
Doug Girgenti | VP, Drug Development | Leadership |
Pete Piliero | VP, Medical Affairs | Leadership |
Jisoo Park | Head, Business Development, Mergers & Acquisitions & Strategy | Leadership |
Tess Ferrer-Turner | Director Clinical Research | Leadership |
Kenneth Touw | Executive Vice President, Regulatory Affairs | Leadership |
Sumner Anderson | Director | Board & advisors |
Jonathan Leff | Director | Board & advisors |
Bryan Sendrowski | Director | Board & advisors |
Kay Clark | Senior Clinical Study Manager | Team |
Marquis Bryant | Manager Regulatory Operations | Team |
Complete people profiles for Cempra
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cempra
3 dated milestones of Cempra across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Cempra is founded.
- Funding First funding round of $22.0M.
- Funding Latest funding round, Post-IPO, of $10.0M.
Competitors of Cempra
Cempra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| nabriva.com | 2006 | Vienna, Austria | $193.08M | – | Pleuromutilin antibiotics are developed for MDR infections. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| cubist.com | 1993 | Lexington, United States | – | 895 | Pharmaceuticals for acute care bacterial infections are developed and commercialized. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| allecra.com | 2013 | – | $44.44M | – | Antibiotics for multi-drug-resistant bacterial infections are developed. |
Detailed competitors of Cempra
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cempra
Websites that share an audience with Cempra (cempra.com).
Websites whose visitors overlap most with Cempra. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| rokabio.com | 100% | 4.2K | #4,841,750 | View details | |
| amagpharma.com | 94% | – | – | View details | |
pharmaregistrations.com | pharmaregistrations.com | 93% | – | – | – |
berlex.com | berlex.com | 93% | – | – | – |
| unither-pharma.com | 92% | 7.7K | #2,502,555 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Cempra
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Cempra
Complete news archive for Cempra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cempra
10 companies that operate in the same segment as Cempra (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cempra
Cempra was founded in 2006.
Cempra is headquartered in Chapel Hill, United States. It is registered at Chapel Hill, North Carolina, United States.
Cempra is a funded company, having raised a total of $149.5M across 8 funding rounds to date. The company's 1st funding round was a Series A of $22M, raised on Oct 2006.
Cempra has 78 employees.
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products - Solithromycin (CEM-101) and TAKSTA (CEM-102, Sodium Fusidate), both in clinical-stage development, address the need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
Cempra's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Cempra has 7 investors. Key investors include Fujifilm, Cubist Pharmaceuticals, Ontario Teachers' Pension Plan, Quaker Partners, and Devon Park BioVentures.
Cempra operates through Cempra Pharmaceuticals, Inc..